Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan.
Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, Maeda T, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Kato T, Hayashi H, Shiraiwa N, Toyoizumi S, Kikkawa H, Thomaidou D, Nishio M. Goto Y, et al. Among authors: imaizumi k. JTO Clin Res Rep. 2023 Mar 24;4(5):100508. doi: 10.1016/j.jtocrr.2023.100508. eCollection 2023 May. JTO Clin Res Rep. 2023. PMID: 37250506 Free PMC article.
Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy.
Nishibe-Toyosato S, Ando Y, Nakasuji N, Hayashi T, Ito K, Matsuda H, Tsujii N, Tsuge M, Imaizumi K, Kawada K, Yamada S. Nishibe-Toyosato S, et al. Among authors: imaizumi k. Biol Pharm Bull. 2023;46(3):505-510. doi: 10.1248/bpb.b22-00374. Biol Pharm Bull. 2023. PMID: 36858580 Free article.
Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes.
Nomura N, Matsumoto H, Yokoyama A, Nishimura Y, Asano K, Niimi A, Tohda Y, Harada N, Nagase H, Nagata M, Inoue H, Kondo M, Horiguchi T, Miyahara N, Hizawa N, Hojo M, Hattori N, Hashimoto N, Yamasaki A, Kadowaki T, Kimura T, Miki M, Taniguchi H, Toyoshima M, Kawamura T, Matsuno O, Sato Y, Sunadome H, Nagasaki T, Oguma T, Hirai T; BEXAS study. Nomura N, et al. Respir Res. 2022 Dec 20;23(1):365. doi: 10.1186/s12931-022-02289-y. Respir Res. 2022. PMID: 36539765 Free PMC article.
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.
Matsuzawa R, Morise M, Ito K, Hataji O, Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. Matsuzawa R, et al. Among authors: imaizumi k. EClinicalMedicine. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38034077 Free PMC article.
993 results